Orthocell Remplir Exempt from US Pharma Tariffs Due to Medical Device Status

Orthocell confirms Remplir exempt from US pharmaceutical tariffs

Regenerative medicine company Orthocell Limited (ASX: OCC) has confirmed its flagship nerve repair product Remplir is not expected to be subject to proposed US pharmaceutical tariffs announced on 2 April 2026. The Orthocell Remplir US tariff exemption stems from the product’s classification as a medical device, placing it outside the scope of Section 232 tariffs targeting pharmaceutical pricing frameworks.

This clarification removes regulatory uncertainty and enables the Company’s US commercial rollout to proceed without pricing disruption or cost pass-through requirements. With approximately 4,000 units of Remplir currently in the US market and 14 US distributors already appointed, none of the existing inventory or commercial relationships are impacted by the proposed measures.

The announcement provides clarity on a potential regulatory overhang that could have complicated the Company’s near-term US revenue trajectory. The distinction between medical device and pharmaceutical classification has proven material in this instance.

Why medical device classification matters

The proposed Section 232 tariffs under the Trade Expansion Act target pharmaceutical products and pricing frameworks specifically. Medical devices, which undergo different regulatory pathways under the US Food and Drug Administration (FDA), are treated separately under US trade policy settings.

Remplir gained US clearance as a medical device for peripheral nerve reconstruction, a designation that sits outside pharmaceutical approval frameworks. This classification provides structural protection from pharmaceutical-specific trade measures, not just the current round of tariffs.

For investors, this distinction carries broader implications beyond tariff exposure. Device classification can provide advantages during periods of pharmaceutical policy reform, where pricing pressures and regulatory changes tend to focus on drug-based therapies rather than medical devices.

The separation between device clearance and drug approval pathways means trade policy often treats these categories differently, even when targeting the same therapeutic areas or patient populations.

Orthocell’s Strategic Position

“The Company believes these factors position Orthocell favourably relative to pharmaceutical-based products and enable it to continue executing on its U.S. growth strategy without disruption or financial impact.”

US market momentum continues

The tariff exemption supports Orthocell’s established US operational footprint without requiring strategic adjustments or financial restructuring. The Company has built distribution infrastructure designed for commercial-scale rollout, with 14 US distributors appointed and approximately 4,000 units of Remplir currently in-market.

Key operational metrics remain intact:

• ~4,000 units of Remplir deployed across US distributor network
• 14 US distributors appointed to support commercial expansion
• None of existing inventory affected by proposed tariff measures
• No pricing adjustments or cost pass-through required

The exemption confirms the Company can continue executing its US growth strategy without disruption to distributor relationships or pricing architecture. For a medical device company in early-stage commercialisation, maintaining momentum without external policy shocks proves material to near-term execution.

Remplir has gained regulatory approvals across multiple jurisdictions, including the US, Australia, New Zealand, Singapore, Thailand, and Canada. The product addresses peripheral nerve reconstruction, a clinical area where device-based approaches compete with pharmaceutical and surgical alternatives.

What investors should watch next

Whilst this announcement removes immediate tariff uncertainty, Orthocell has confirmed it will continue monitoring US trade policy developments and update the market as required. The Company’s focus remains on commercial execution rather than regulatory risk management.

Near-term catalysts for investors include:

• US sales momentum: Quarterly updates on Remplir unit sales and distributor performance
• Regulatory expansion: Potential additional approvals in new jurisdictions
• Policy clarity: Any changes to Section 232 scope or medical device treatment

The Company’s broader product portfolio includes Striate+ for dental guided bone regeneration (distributed globally by BioHorizons Implant Systems Inc) and autologous cell therapies targeting tendon and cartilage tissue regeneration. Striate+ holds clearances across the US, Australia, New Zealand, Singapore, UK, Europe, Canada, and Brazil.

Orthocell is also advancing its tendon cell therapy programme in the US through technology transfer and FDA engagement to confirm the regulatory pathway and prepare for partnering discussions. These programmes sit outside the current tariff discussion but represent additional commercial optionality.

For Remplir specifically, the combination of tariff exemption, established distribution infrastructure, and in-market inventory positions the Company to continue building US commercial traction without the pricing headwinds facing pharmaceutical-based competitors. The next test will be demonstrating sustained sales growth through the distributor network already in place.

Don’t Miss the Next Healthcare Breakthrough

Join 20,000+ investors getting FREE breaking ASX news delivered to your inbox within minutes, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to start receiving healthcare alerts the moment market-moving announcements hit the ASX.